New mobile scanner aims to sharpen lung biopsy images

NCT ID NCT07149597

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will test a new mobile 4D CBCT scanner that creates 3D images of lung lesions during a biopsy procedure. Researchers want to see if the images are clear and accurate enough to help doctors diagnose peripheral lung lesions. Fifty adults with small to medium-sized lung spots will be enrolled, and the scanner's images will be compared to standard CT scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Mobile 4D CBCT imaging device

What this could lead to

If successful, this could provide clearer, real-time 3D images during lung biopsies, potentially improving diagnostic accuracy and reducing the need for repeat procedures.

What could go wrong

This is a small, early-stage validation study with only 50 participants. The technology may not prove significantly better than current imaging, and image quality depends on expert scoring, which is subjective.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL PULMONARY LESIONS (PPLS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai Chest Hospital

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••